Wolverine

Wolverine is a two-component research blend supplied in a single lyophilized vial: 10MG BPC-157 and 10MG TB-500. Each component has its own published literature, almost all of it from cell culture and rodent models, and only one controlled experiment indexed in PubMed has tested the two together. This guide summarizes what has been reported for each component, states the study model for every finding, and describes that one combined study.

BPC-157

BPC stands for body protection compound, the name its discoverers gave to a protein isolated from human gastric juice; BPC-157 is a partial sequence of that protein (Chang et al., 2011). Most of its literature comes from the discovering group. In rat gastric mucosa the peptide was studied alongside agents that block or supply nitric oxide (Sikirić et al., 1997), and a four-week rat model of short bowel syndrome tracked body weight, villus height and anastomosis strength in BPC-157 groups (Sever et al., 2009).

A separate group reported increased outgrowth from rat tendon explants and higher fibroblast survival and migration, with activation of the FAK-paxillin pathway (Chang et al., 2011). The BPC-157 research guide covers it in full.

TB-500 and thymosin beta-4

Analytical work on material sold as TB-500 identified the acetylated 17 to 23 fragment of thymosin beta-4, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, and confirmed it by independent synthesis (Esposito et al., 2012). A doping-control method study described the same fragment as a synthetic version of an active region of the parent protein (Ho et al., 2012).

Most biological data concern the full 43-residue protein: in a rat full-thickness wound model thymosin beta-4 increased re-epithelialization and collagen deposition and stimulated keratinocyte migration in culture (Malinda et al., 1999), and in cardiac cells it formed a complex with PINCH and integrin-linked kinase that activates Akt, with higher integrin-linked kinase and Akt activity in mouse hearts after coronary ligation (Bock-Marquette et al., 2004). Results for the full protein should not be assumed to carry over to the fragment.

A single published experiment compared four groups in one rat Achilles transection and repair model: control, BPC-157, TB-500 and the two combined. At four weeks it reported a significant biomechanical advantage in the TB-500 group and no additive effect from the combination (Biçer et al., 2026).

It is the only controlled experiment on the pair indexed in PubMed. There are no data on how the two interact in solution or on stability of the combined material, so studies using Wolverine should handle it as a defined mixture and include controls for each component. The BPC-157 vs TB-500 comparison sets the two side by side.